Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.41 |
| ▸ | ITGAV | P06756 | 4/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.41 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.41 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.41 |
| ▸ | ITGB8 | P26012 | 4/20 | 0.41 |
| ▸ | ITGA8 | P53708 | 4/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.35 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25624224 | 0.93 | ITGB3 (0.39) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24037104 | 0.91 | GPR139 (0.37) | CACNA1BAURKBALDH1A1HPGDKDM4E | |
| SCHEMBL24036910 | 0.89 | ITGB3 (0.47) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24036908 | 0.89 | MAPT (0.38) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24036907 | 0.89 | ITGB3 (0.37) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL30546801 | 0.88 | NOTUM (0.41) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL25624219 | 0.88 | NOTUM (0.41) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24036909 | 0.88 | ITGB3 (0.37) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL24036814 | 0.87 | HPGD (0.35) | CACNA1BAURKBALDH1A1HPGDKDM4E | |
| SCHEMBL25753881 | 0.87 | HPGD (0.35) | CACNA1BAURKBALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE CORP (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4431098-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | UBE Corporation (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | ITGB3 4177/4885ITGB1 4421/4885ITGAV 4406/4885 |
| US-20250049806-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | CYP21A2, HSD11B2, MC2R | ITGB3 4105/4885ITGB1 4533/4885ITGAV 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.